Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 850 results for "gilead sciences"

Deutsche Bank Reaffirms Buy Rating for Gilead Sciences (GILD)
American Banking News - Forex

Deutsche Bank Reaffirms Buy Rating for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ:GILD)s stock had its buy rating reissued by research analysts at Deutsche Bank in a report released on Saturday. They currently have a $125.00 price target on the biopharmaceutical research company's stock. Deutsche Bank's ... American Banking News - Forex, 23 hours ago
Gilead Sciences Given Overweight Rating at Morgan Stanley (GILD) American Banking News - Forex, 1 day ago

60 images for gilead sciences

American Banking News, 23 hours ago
MSN News US, 3 days ago
Drug Discovery and Development, 3 days ago
Jutia Group, 3 weeks ago, 4 weeks ago
Nasdaq, 4 days ago
Nasdaq, 3 days ago
Nasdaq, 3 days ago
Milwaukee Journal Sentinel, 3 days ago, 3 days ago

Can Gilead keep growing without a big deal?

Gilead Sciences GILD But for Kempler, the ride is over for now. Sales of those hep-C drugs, Sovaldi and Harvoni, are plateauing, and Gilead stayed mostly on the sidelines during a recent pharmaceutical-deal frenzy, declining to refresh its product ...
 Fortune1 day ago

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Update

Gilead Sciences, Inc. ( NASDAQ:GILD ) has had quite an eventful month so far, with the company's stock seeing a 10% gain in May 2015. The share price followed a declining trend in the first part of the month reaching a low of $100.1 on May 7, after ...
 Bidness Etc4 days ago Insider Selling: Gilead Sciences, Inc. (GILD), Electronic Arts Inc. (EA) & Zynga Inc (ZNGA)  Bidness Etc4 days ago Gilead Sciences, Inc. Being Urged By Activists To Offer Higher Discounts On Sovaldi  Bidness Etc4 days ago Gilead To Present At The 2015 Global Healthcare Conference On Tuesday, May 19  BioSpace5 days ago

Gilead Sciences Rises 1.56% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $109.36 to a high of $111.33. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $110.24 on volume of 13.7 million shares. ...
 Individual.com6 days ago Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.56% Rise  Individual.com6 days ago Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.21%  Individual.com1 week ago SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.77% Loss  Individual.com3 weeks ago

Shares of Gilead Sciences Under Pressure, Down 1.3%

Gilead Sciences (NASDAQ:GILD) is one of today's biggest movers, down 0.9% to $109.61. The S&P is currently trading fractionally lower to 2,125 and the Dow Jones Industrial Average is trading fractionally lower
 Individual.com4 days ago
Motley Fool

Johnson & Johnson Takes On Gilead Sciences in Hep C... Again

Hepatitis C treatment has been among the most dynamically changing markets in biotechnology. A host of companies are knee-deep in developing new, more effective treatments, but few have been as successful as Gilead Sciences (NASDAQ: GILD Less than ...
 Motley Fool4 days ago J&J to submit 10 new medicines for approval  The Gulf Today1 hour ago

Activists challenge Gilead to give up Hep C drug patent

Singapore: Initiative for Medicines, Access & Knowledge (I-MAK), a team of lawyers and scientists campaigning for global accessibility of medicines for hepatitis C and HIV patients, has challenged Gilead for seeking illegitimate patents for ...
 Bio Spectrum Asia3 days ago
Tech Times

Gilead patents on costly hepatitis C drug challenged in 5 countries

NEW YORK, May 20 (Reuters) - A U.S. group is trying to block patents in five countries for Gilead Sciences Inc's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In ...
 CNBC4 days ago U.S. Group Challenges Gilead's Hepatitis C Drug Patents In 5 Countries  Kaiser Network.org3 days ago Gilead Fights For Hepa C Drug Patents: Activists Concerned About Drug Accessibility  Tech Times2 days ago Activists Challenge Gilead's Patents on Costly Hepatitis C Drug Sovaldi  MSNBC Newsweek3 days ago
Motley Fool

SWOT Analysis of Gilead Sciences Inc. Stock

What's the outlook for Gilead Sciences' (NASDAQ: GILD Over the short run, that question is next to impossible to answer. Over the long run, though, investors can project how well Gilead stock (or any other stock, for that matter) should perform ...
 Motley Fool4 days ago

Gilead Just Presented 'Interesting' Data, Analysts Say

In a report published Wednesday, Morgan Stanley analysts maintained an Overweight rating on Gilead Sciences, Inc. (NASDAQ: GILD), after the company presented data from its phase 1 trial of GS-5745 in moderate-to-severe active ulcerative colitis. ...
 Benzinga.com4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less